Perfluorohexyloctane
Medication for dry eye disease
From Wikipedia, the free encyclopedia
Perfluorohexyloctane (branded as Evotears, Miebo,[a] and Novatears, among others) is a medication used for the treatment of dry eye disease.[4] It is a semifluorinated alkane.[4]
Miebo (/ˈmaɪboʊ/ MY-bow)
Novatears
 | |
| Clinical data | |
|---|---|
| Trade names | Evotears Miebo (/ˈmaɪboʊ/ MY-bow) Novatears |
| Other names | NOV03; 1-(perfluorohexyl)octane |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a623054 |
| License data | |
| Routes of administration | Eye drops |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C14H17F13 |
| Molar mass | 432.269 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Perfluorohexyloctane has been available in multiple markets since 2015 under the brand names Evotears and Novatears,[5] and was additionally approved for medical use in the United States in May 2023 under the brand name Miebo.[4][6] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.[7]
Medical uses
Perfluorohexyloctane is indicated for the treatment of the signs and symptoms of dry eye disease.[4][8][9]
Availability
Perfluorohexyloctane is sold as an over-the-counter medication under the brand names Evotears and Novatears in multiple countries,[10] costing around NZ$34.00, A$30, and €30 for a one-month supply.
In the US, perfluorohexyloctane is sold under the brand name Miebo; a prescription is required. Perfluorohexyloctane (also under the brand name Miebo) was approved by Health Canada in September 2024.[11]
Side effects
Blurred vision and conjunctival redness are among the side effects of this drug.[12]
